Aranesp® (darbepoetin alfa) |
||
| ARANESP® (darbepoetin alfa) is indicated for the treatment of anaemia associated with chronic renal failure (CRF). Aranesp® is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy. |
||
Neulasta® (pegfilgrastim) |
||
| Neulasta® is indicated for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia and so reduce the incidence of infection, as manifested by febrile neutropenia. |
||
NEUPOGEN® (Filgrastim) |
||
| NEUPOGEN® (Filgrastim) NEUPOGEN® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation. NEUPOGEN® is indicated for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. |
||
Nplate® (romiplostim) |
||
| Nplate® is indicated for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who are (1) non-splenectomised and have had an inadequate response, or are intolerant, to both corticosteroids and immunoglobulins;. (2) splenectomised and have had an inadequate response to splenectomy. |
||
Sensipar® (cinacalcet HCl) |
||
| Sensipar® is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as the treatment of hypercalcemia in patients with parathyroid carcinoma. It was approved by the FDA in 2004. |
||
Vectibix® (panitumumab) |
||
| Vectibix® is indicated for treatment of epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal carcinoma in patients with non-mutated (wild-type) Kirsten rat sarcoma 2 viral oncogene homologue (KRAS) who have disease progression following treatment with fluoropyrimidine, oxaliplatin- and irinotecan-based chemotherapy. |
||
Total of 6 Products |
||
